Neuropsychiatric manifestations of depression in multiple sclerosis: Neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression

Dialogues in Clinical Neuroscience

Volumn 9, Issue 2, 2007, Pages 125-139

  Pucak, Michele L ^a   Carroll, Katherine A L ^a   Kerr, Douglas A ^a   Kaplin, Adam I ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Cytokine; Hypothalamic pituitary adrenal axis; Inflammation; Interferon; Neuroimaging; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; BETA INTERFERON; BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; GLATIRAMER; INTERFERON BETA SERINE; INTERLEUKIN 1BETA; INTERLEUKIN 2; LITHIUM; METYRAPONE; MIFEPRISTONE; PRASTERONE; REBOXETINE; VALPROIC ACID;

ADJUVANT THERAPY; ANOREXIA; ARTICLE; ASTHENIA; BECK DEPRESSION INVENTORY; BIPOLAR DISORDER; BRAIN ATROPHY; CANCER; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DEGENERATIVE DISEASE; DEPRESSION; DISEASE ASSOCIATION; DRUG MEGADOSE; EUPHORIA; FATIGUE; FLU LIKE SYNDROME; FUNCTIONAL DISEASE; HEPATITIS C; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE FUNCTION TEST; IMMUNOPATHOLOGY; INSOMNIA; IRRITABILITY; MAJOR DEPRESSION; MEMORY DISORDER; MOOD DISORDER; MULTIPLE SCLEROSIS; NEUROENDOCRINE SYSTEM; NEUROIMAGING; NEUROPSYCHIATRY; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; QUALITY OF LIFE; SIDE EFFECT; SLEEP DISORDER; SUICIDAL BEHAVIOR; SYMPTOMATOLOGY;

ANIMALS; BRAIN; CYTOKINES; DEPRESSIVE DISORDER; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNE SYSTEM; INTERFERONS; MULTIPLE SCLEROSIS; PITUITARY-ADRENAL SYSTEM; STRESS, PSYCHOLOGICAL;

EID: 34447572611     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (166)

1. Anderson DW, Ellenberg JH, Leventhal CM, et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol. 1992;31:333-336.
2. Ehde DM, Bombardier CH. Depression in persons with multiple sclerosis. Phys Med Rehabil Clin N Am. 2005;16:437-448.
3. Feinstein A. The neuropsychiatry of multiple sclerosis. Can J Psychiatry. 2004;49:157-163.
4. Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler. 2005;11:328-337.
5. Mohr DC Goodkin DE, Islar J, Hauser SL, Genain CP. Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch Neurol. 2001;58:1081-1086.
6. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry. 2005;76:469-475.
7. Butler MA, Bennett TL. In search of a conceptualization of multiple sclerosis: a historical perspective. Neuropsychol Rev. 2003;13:93-112.
8. Caine ED, Schwid SR. Multiple sclerosis, depression, and the risk of suicide. Neurology. 2002;59:662-663.
9. Lobentanz IS, Asenbaum S, Vass K, et al. Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand. 2004;110:6-13.
10. Benedict RH, Wahlig E, Bakshi R, et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci. 2005;231:29-34.
11. Fruehwald S, Loeffler-Stastka H, Eher R, Saletu B, Baumhackl U. Depression and quality of life in multiple sclerosis. Acta Neurol Scand. 2001;104:257-261.
12. Provinciali L, Ceravolo MG, Bartolini M, Logullo F, Danni M. A multidimensional assessment of multiple sclerosis: relationships between disability domains. Acta Neurol Scand. 1999;100:156-162.
13. King KE, Arnett PA. Predictors of dyadic adjustment in multiple sclerosis. Mult Scler. 2005;11:700-707.
14. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology. 1991;41:1193- 1196.
15. Rabkin JG, Albert SM, Del Bene ML, et al. Prevalence of depressive disorders and change overtime in late-stage ALS. Neurology. 2005;65:62-67.
16. Feinstein A, O'Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression. A prospective investigation. J Neurol. 2002;249:815-820.
17. McGuigan C, Hutchinson M. Unrecognised symptoms of depression in a community-based population with multiple sclerosis. J Neurol. 2006;253:219-223.
18. Patten SB, Metz LM. Depression in multiple sclerosis. Psychother Psychosom. 1997;66:286-292.
19. Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology. 1996;46:628-632.
20. Dalos NP, Rabins PV, Brooks BR, O'Donnell P. Disease activity and emotional state in multiple sclerosis. Ann Neurol. 1983;13:573-577.
21. Fassbender K, Schmidt R, Mossner R, et al. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch Neurol. 1998;55:66-72.
22. Kroencke DC, Denney DR, Lynch SG. Depression during exacerbations in multiple sclerosis: the importance of uncertainty. Mult Scler. 2001;7:237-242.
23. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev. 2005;29:891-909.
24. Foley FW, Traugott U, LaRocca NG, et al. A prospective study of depression and immune dysregulation in multiple sclerosis. Arch Neurol. 1992;49:238-244.
25. Rabins PV, Brooks BR, O'Donnell P, et al. Structural brain correlates of emotional disorder in multiple sclerosis. Brain. 1986;109:585-597.
26. Pujol J, Bello J, Deus J, Marti-Vilalta JL, Capdevila A. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology. 1997;49:1105-1110.
27. Feinstein A, Roy P, Lobaugh N, et al. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology. 2004;62:586-590.
28. Zorzon M, de Masi R, Nasuelli D, et al. Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol. 2001;248:416-421.
29. Bakshi R, Czarnecki D, Shaikh ZA, et al. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport. 2000;11:1153-1158.
30. Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol. 2003;250:1407-1419.
31. Cifelli A, Arridge M, Jezzard P, et al. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol. 2002;52:650-653.
32. Kutzelnigg A, Lassmann H. Cortical lesions and brain atrophy in MS. J Neurol Sci. 2005;233:55-59.
33. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol. 2000;47:391-395.
34. Gadea M, Martinez-Bisbal MC, Marti-Bonmati L, et al. Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. Brain. 2004;127:89-98.
35. Sastre-Garriga J, Ingle GT, Chard DT, et al. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol. 2005;62:569-573.
36. Staffen W, Zauner H, Mair A, et al. Magnetic resonance spectroscopy of memory and frontal brain region in early multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2005;17:357-363.
37. Yildiz-Yesiloglu A, Ankerst DP. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res. 2006;147:1-25.
38. Asnis GM, Sachar EJ, Halbreich U, et al. Cortisol secretion and dexamethasone response in depression. Am J Psychiatry. 1981;138:1218-1221.
39. Lenox RH, Peyser JM, Rothschild B, Shipley J, Weaver L. Failure to normalize the dexamethasone suppression test: association with length of illness. Biol Psychiatry. 1985;20:333-337.
40. Targum SD. Persistent neuroendocrine dysregulation in major depressive disorder: a marker for early relapse. Biol Psychiatry. 1984;19:305-318.
41. Banki CM, Bissette G, Arato M, O'Connor L, Nemeroff CB. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry. 1987;144:873-877.
42. Owens MJ, Nemeroff CB. The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found Symp. 1993;172:296-308;discussion 308-316.
43. Nemeroff CB, Bissette G, Akil H, Fink M. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry. 1991;158:59-63.
44. Nikisch G, Mathe AA, Czernik A, et al. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology (Berl). 2005;181:751-760.
45. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516-1518.
46. Gomez RG, Fleming SH, Keller J, et al. The neuropsychological profile of psychotic major depression and its relation to cortisol. Biol Psychiatry. 2006;60:472-478.
47. Gold SM, Mohr DC, Huitinga I, et al. The role of stress-response systems for the pathogenesis and progression of MS. Trends Immunol. 2005;26:644-652.
48. Gold SM, Raji A, Huitinga I, et al. Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis. J Neuroimmunol. 2005;165:186-191.
49. Wada K, Yamada N, Sato T, et al. Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures. Psychosomatics. 2001;42:461-466.
50. Sirois F. Steroid psychosis: a review. Gen Hosp Psychiatry. 2003;25:27-33.
51. Kronfol Z. Immune dysregulation in major depression: a critical review of existing evidence. Int J Neuropsychopharmacol. 2002;5:333-343.
52. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:11-38.
53. Weisse CS. Depression and immunocompetence: a review of the literature. Psychol Bull. 1992;111:475-489.
54. Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom Med. 2003;65:347-356.
55. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2004;164:1010-1014.
56. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol. 2002;90:1279-1283.
57. Sluzewska A, Rybakowski J, Bosmans E, et al. Indicators of immune activation in major depression. Psychiatry Res. 1996;64:161-167.
58. Kahl KG, Kruse N, Faller H, Weiss H, Rieckmann P. Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology. 2002;27:671-681.
59. Aarli JA. Role of cytokines in neurological disorders. Curr Med Chem. 2003;10:1931-1937.
60. Baraczka K, Nekam K, Pozsonyi T, Szuts I, Ormos G. Investigation of cytokine (tumor necrosis factor-alpha, interleukin-6, interleukin-10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus. Eur J Neurol. 2004;11:37-42.
61. Malmestrom C, Andersson BA, Haghighi S, Lycke J. IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles. J Neuroimmunol. 2006;175:176- 182.
62. Anisman H, Merali Z, Poulter MO, Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des. 2005;11:963-972.
63. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:201-217.
64. Smith RS. The macrophage theory of depression. Med Hypotheses. 1991;35:298-306.
65. Pucak ML, Kaplin AI. Unkind cytokines: current evidence for the potential role of cytokines in immune-mediated depression. Int Rev Psychiatry. 2005;17:477-483.
66. Frommberger UH, Bauer J, Haselbauer P, et al. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci. 1997;247:228-233.
67. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000;22:370-379.
68. Levine J, Barak Y, Chengappa KN, et al. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 1999;40:171-176.
69. Anisman H, Ravindran AV, Griffiths J, Merali Z. Interleukin-1 beta production in dysthymia before and after pharmacotherapy. Biol Psychiatry. 1999;46:1649-1655.
70. Zautra AJ, Yocum DC, Villanueva I, et al. Immune activation and depression in women with rheumatoid arthritis. J Rheumatol. 2004;31:457-463.
71. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol. 2002;22:86-90.
72. Wichers MC, Kenis G, Leue C, et al. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry. 2006;60:77-79.
73. Goeb JL, Even C, Nicolas G, et al. Psychiatric side effects of interferon-beta in multiple sclerosis. Eur Psychiatry. 2006;21:186-193.
74. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26:643-652.
75. Pollak Y, Ovadia H, Orion E, Weidenfeld J, Yirmiya R. The EAE-associated behavioral syndrome: I. Temporal correlation with inflammatory mediators. J Neuroimmunol. 2003;137:94-99.
76. Pollak Y, Ovadia H, Orion E, Yirmiya R. The EAE-associated behavioral syndrome: II. Modulation by anti-inflammatory treatments. J Neuroimmunol. 2003;137:100-108.
77. Okuda Y, Sakoda S, Bernard CC, et al. IL-6-def icient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int Immunol. 1998;10:703-708.
78. Mohr DC, Pelletier D. A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis. Brain Behav Immun. 2006;20:27-36.
79. Maes M, Song C, Lin A, et al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine. 1998;10:313-318.
80. Maes M, Lin AH, Delmeire L, et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry. 1999;45:833-839.
81. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003;160:1554-1565.
82. Zhou D, Kusnecov AW, Shurin MR, DePaoli M, Rabin BS. Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology. 1993;133:2523-2530.
83. Song C, Merali Z, Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience. 1999;88:823-836.
84. Zhou D, Shanks N, Riechman SE, et al. Interleukin 6 modulates interleukin-1-and stress-induced activation of the hypothalamic-pituitary- adrenal axis in male rats. Neuroendocrinology. 1996;63:227-236.
85. Mohr DC, Hart SL, Julian L, Cox D, Pelletier D. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ. 2004;328:731.
86. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351-1362.
87. Maes M, Bosmans E, Meltzer HY. Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. Eur Arch Psychiatry Clin Neurosci. 1995;245:172-178.
88. Maes M, Scharpe S, Meltzer HY, et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res. 1993;49:11-27.
89. Capuron L, Raison CL, Musselman DL, et al. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry. 2003;160:1342-1345.
90. Young EA, Haskett RF, Murphy-Weinberg V, Watson SJ, Akil H. Loss of glucocorticoid fast feedback in depression. Arch Gen Psychiatry. 1991;48:693-699.
91. Perlstein RS, Whitnall MH, Abrams JS, Mougey EH, Neta R. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology. 1993;132:946-952.
92. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5:2516-2522.
93. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov. 2002;1:609-620.
94. Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci. 2004;29:11-17.
95. Bell C, Abrams J, Nutt D. Tryptophan depletion and its implications for psychiatry. Br J Psychiatry. 2001;178:399-405.
96. Capuron L, Ravaud A, Neveu PJ, et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002;7:468-473.
97. Maes M, Meltzer HY, Scharpe S, et al. Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res. 1993;49:151-165.
98. Ramamoorthy S, Ramamoorthy JD, Prasad PD, et al. Regulation of the human serotonin transporter by interleukin-1 beta. Biochem Biophys Res Commun. 1995;216:560-567.
99. Morikawa O, Sakai N, Obara H, Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol. 1998;349:317-324.
100. Gould E, McEwen BS. Neuronal birth and death. Curr Opin Neurobiol. 1993;3:676-682.
101. Taupin P, Gage FH. Adult neurogenesis and neural stem cells of the central nervous system in mammals. J Neurosci Res. 2002;69:745-749.
102. Sapolsky RM. Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry. 2004;56:137-139.
103. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A. 1996;93:3908-3913.
104. Gould E, Tanapat P, McEwen BS, Flugge G, Fuchs E. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci U S A. 1998;95:3168-3171.
105. Vallieres L, Campbell IL, Gage FH, Sawchenko PE. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci. 2002;22:486-492.
106. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003;302:1760-1765.
107. Kaneko N, Kudo K, Mabuchi T, et al. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacol. 2006;31:2619-2626.
108. Aharoni R, Arnon R, Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J Neurosci. 2005;25:8217-8228.
109. Castren E, Voikar V, Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol. 2007;7:18-21.
110. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116-1127.
111. Tsankova NM, Berton O, Renthal W, et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006;9:519-525.
112. Gervasoni N, Aubry JM, Bondolfi G, et al. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology. 2005;51:234-238.
113. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54:70-75.
114. Levinson DF. The genetics of depression: a review. Biol Psychiatry. 2006;60:84-92.
115. Schumacher J, Jamra RA, Becker T, et al. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry. 2005;58:307-314.
116. Koponen E, Rantamaki T, Voikar V, et al. Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines. Cell Mol Neurobiol. 2005;25:973-980.
117. Sarchielli P, Greco L, Stipa A, Floridi A, Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol. 2002;132:180-188.
118. Hayley S, Poulter MO, Merali Z, Anisman H. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience. 2005;135:659-678.
119. Borras C, Rio J, Porcel J, et al. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b. Neurology. 1999;52:1636-1639.
120. Tsai SJ. Glatiramer acetate could be a potential antidepressant through its neuroprotective and anti-inflammatory effects. Med Hypotheses. 2007;69:145-148.
121. Weber MS, Prod'homme T, Steinman L, Zamvil SS. Drug Insight: using statins to treat neuroinflammatory disease. Nat Clin Pract Neurol. 2005;1:106-112.
122. Young-Xu Y, Chan KA, Liao JK, Ravid S, Blatt CM. Long-term statin use and psychological well-being. J Am Coll Cardiol. 2003;42:690-697.
123. Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med. 2003;163:1926-1932.
124. Ormiston T, Wolkowitz OM, Reus VI, Manfredi F. Behavioral implications of lowering cholesterol levels: a double-blind pilot study. Psychosomatics. 2003;44:412-414.
125. Brunello N, Alboni S, Capone G, et al. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int Clin Psychopharmacol. 2006;21:219-225.
126. Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680-684.
127. Pavlov VA, Tracey KJ. Controlling inflammation: the cholinergic anti-inflammatory pathway. Biochem Soc Trans. 2006;34:1037-1040.
128. Maes M. The immunoregulatory effects of antidepressants. Hum Psychopharmacol. 2001;16:95-103.
129. Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol. 2006;6:903-907.
130. Chiou SH, Chen SJ, Peng CH, et al. Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell. Biochem Biophys Res Commun. 2006;343:391-400.
131. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20:9104-9110.
132. Manev H, Uz T, Smalheiser NR, Manev R. Antidepressants alter cell proliferation in the adult brain in vivo and in neural cultures in vitro. Eur J Pharmacol. 2001;411:67-70.
133. Czeh B, Michaelis T, Watanabe T, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. PNAS. 2001;98:12796-12801.
134. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805-809.
135. Brown J, Cooper-Kuhn CM, Kempermann G, et al. Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis. Eur J Neurosci. 2003;17:2042-2046.
136. Madsen TM, Treschow A, Bengzon J, et al. Increased neurogenesis in a model of electroconvulsive therapy. Biol Psychiatry. 2000;47:1043-1049.
137. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002;5:401-412.
138. Reynolds JL, Ignatowski TA, Sud R, Spengler RN. Brain-derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant. J Pharmacol Exp Ther. 2004;310:1216-1225.
139. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry. 2001;49:391-404.
140. Hu F, Wang X, Pace TW, Wu H, Miller AH. Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Mol Psychiatry. 2005;10:426-428.
141. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry. 1999;156:646-649.
142. Kalimi M, Shafagoj Y, Loria R, Padgett D, Regelson W. Anti-glucocorticoid effects of dehydroepiandrosterone (DHEA). Mol Cell Biochem. 1994;131:99-104.
143. Tellez N, Comabella M, Julia E, et al. Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. Mult Scler. 2006;12:487-494.
144. Ravaris CL, Sateia MJ, Beroza KW, Noordsy DL, Brinck-Johnsen T. Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman. Arch Gen Psychiatry. 1988;45:966-967.
145. Jahn H, Schick M, Kiefer F, et al. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry. 2004;61:1235-1244.
146. Murphy BE. Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology. 1997;22(suppl 1):S125-S132.
147. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology. 2006;31:628-636.
148. Zoumakis E, Grammatopoulos DK, Chrousos GP. Corticotropin-releasing hormone receptor antagonists. Eur J Endocrinol. 2006;155:S85-S91.
149. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260-265.
150. Saarelainen T, Hendolin P, Lucas G, et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci. 2003;23:349-357.
151. Sairanen M, Lucas G, Ernfors P, Castren M, Castren E. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci. 2005;25:1089-1094.
152. Monteggia LM, Barrot M, Powell CM, et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A. 2004;101:10827-10832.
153. Vaidya VA, Siuciak JA, Du F, Duman RS. Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures. Neuroscience. 1999;89:157-166.
154. Blanco Y, Moral EA, Costa M, et al. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Neurosci Lett. 2006;406:270-275.
155. Aharoni R, Eilam R, Domev H, et al. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A. 2005;102:19045-19050.
156. Ziemssen T, Kumpfel T, Schneider H, et al. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy. J Neurol Sci. 2005;233:109-112.
157. Caggiula M, Batocchi AP, Frisullo G, et al. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol. 2005;62:176-182.
158. Caggiula M, Batocchi AP, Frisullo G, et al. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin Immunol. 2006;118:77-82.
159. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl). 2001;158:100-106.
160. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem. 2000;75:1729-1734.
161. Chen G, Manji K. The extracelular signal-related kinase pathway: an emerging promising target for mood stabilizers. Curr Opin Psychiatry. 2006;19:313-323.
162. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45:1277-1285.
163. Patten SB, Francis G, Metz LM, et al. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler. 2005;11:175-181.
164. Puri BK, Bydder GM, Chaudhuri KR, et al. MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine. Neuroreport. 2001;12:1821-1824.
165. Glaser R, Robles TF, Sheridan J, Malarkey WB, Kiecolt-Glaser JK. Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch Gen Psychiatry. 2003;60:1009-1014.
166. Varghese AK, Verdu EF, Bercik P, et al. Antidepressants attenuate increased susceptibility to colitis in a murine model of depression. Gastroenterology. 2006;130:1743-1753.